CureVac: European Patent Office Largely Rejects Opposition From BioNTech in Patent Disputes!
Reading Time: 2 minutes
CureVac NV (i.) is a globally active biopharmaceutical company focused on the development of drugs based on messenger RNA (mRNA). The company develops prophylactic vaccines, cancer therapies, antibody therapies, and treatments for rare diseases based on mRNA technology. A key focus is the development of second-generation vaccines against COVID-19 and seasonal flu, in collaboration with GlaxoSmithKline (GSK). In 2024, CureVac initiated a strategic realignment to concentrate resources on high-quality mRNA programs. This restructuring included a reduction...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
